Europital, a global provider of medical management services for clinical research and drug development, is opening a UK site to further expand its services to the UK biotech industry. The company is already working with a number of UK partners and is forecasting compound growth nearly 30% of the next three years.
 
The Europital site will expand its operational team over the next few months and will target working with small and medium biotechs to design & execute projects, particularly for First in Man, Phase I and Phase II clinical studies.
 
“We already partner with several biotechs in the UK and what we have seen is that there is a clear gap in the market for small innovators looking for a science focused CRO that can provide the detailed knowledge and therapeutic experience. Gaining access to senior medical CRO expertise can be extremely challenging for the smaller innovators. What they need is a partner to bring a medical department with real-world trial experience to implement study design and protocols and be a scientific driving force behind project’s success,” commented Dr. Mohamed El Malt, CEO and chief medical officer of Europital.
 
Europital is planning to quickly expand its offerings and will focus on providing expertise to partners in complex oncology indications, inflammatory diseases, and immunology & infectious disease studies. The UK site opening will be used to leverage the company’s phase iii experience with clinical studies directly conducted at UK investigative sites.
 
“It’s a really exciting time for innovators in the UK and the four biotech hubs have a really vibrant pipeline of candidates. But, much of this cutting-edge innovation lies with smaller companies and spin outs that really need the help of a science driven CRO – not a volume driven large CRO that usually won’t give the study the attention it needs. You often hear ‘follow the molecule’ in CRO circles. What we are doing is following the innovator and looking at where we can best help partners advance targets more quickly through clinical trials. There is a real shortage of senior experience in the market because of the number of trials underway. It is then perhaps unsurprising that we have seen almost 100% repeat business and we expect to see rapid growth in client demand. We add value to each step of their projects from study design until conclusion. And, this development also opens up direct access to UK investigational sites for our existing European and North American partners with phase iii studies. But this latest announcement is part of wider expansion, so there will be more news to follow imminently,” added El Malt.